MedPath

Shionogi, Inc

🇯🇵Japan
Ownership
-
Established
1919-01-01
Employees
-
Market Cap
$13.1B
Website
https://www.shionogi.com/jp/ja/

Safety and Efficacy Study of S-309309 in Obese Adults

Phase 2
Completed
Conditions
Obesity
Interventions
Drug: Placebo
First Posted Date
2023-06-29
Last Posted Date
2025-04-16
Lead Sponsor
Shionogi
Target Recruit Count
365
Registration Number
NCT05925114
Locations
🇺🇸

Catalina Research Institute, Montclair, California, United States

🇺🇸

L MARC Research Center, Louisville, Kentucky, United States

🇺🇸

Be Well Clinical Studies LLC, Lincoln, Nebraska, United States

and more 45 locations

Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection

Phase 3
Completed
Conditions
SARS-CoV-2 Infection
Interventions
Drug: Placebo
First Posted Date
2023-06-09
Last Posted Date
2025-04-17
Lead Sponsor
Shionogi
Target Recruit Count
2387
Registration Number
NCT05897541
Locations
🇺🇸

Florida Research Center, Inc., Miami, Florida, United States

🇯🇵

Tashiro Endocrinolgy Clinic, Fukuoka-shi, Fukuoka, Japan

🇯🇵

Yotsuya Naika, Shinjuku-Ku, Tokyo, Japan

and more 175 locations

Use of Cefiderocol in the Management of Gram-Negative Infections

Completed
Conditions
Gram-Negative Infection
Interventions
First Posted Date
2023-03-29
Last Posted Date
2023-06-26
Lead Sponsor
Shionogi
Target Recruit Count
314
Registration Number
NCT05789199
Locations
🇪🇸

Complejo Hospitalario Universitario de Albacete, Albacete, Spain

🇪🇸

Hospital Universitario Torrecardenas, Almeria, Almeria, Spain

🇪🇸

Hospital General Universitario Gregorio Marañón, Madrid, Spain

and more 52 locations

Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids

Phase 1
Recruiting
Conditions
Opioid-Induced Constipation (OIC)
Interventions
First Posted Date
2022-10-20
Last Posted Date
2025-04-20
Lead Sponsor
Shionogi
Target Recruit Count
24
Registration Number
NCT05588323
Locations
🇦🇱

University Center Mother Theresa , Hospital - Onco-hematology department, Tirana, Albania

🇦🇲

Yeolyan Hematology. , and Oncology Center -, Yerevan, Armenia

🇧🇪

CHU Saint-Pierre Clinical Trials Unit, Brussels, Belgium

and more 13 locations

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
First Posted Date
2022-06-08
Last Posted Date
2023-05-26
Lead Sponsor
Shionogi
Target Recruit Count
25
Registration Number
NCT05409911
Locations
🇺🇸

Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

🇺🇸

Advanced Pharma CR, LLC, Miami, Florida, United States

🇺🇸

Nucleus Network, Saint Paul, Minnesota, United States

and more 1 locations

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2022-05-27
Last Posted Date
2023-12-14
Lead Sponsor
Shionogi
Target Recruit Count
14
Registration Number
NCT05395104
Locations
🇺🇸

Worldwide Clinical Trials, San Antonio, Texas, United States

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

Phase 1
Completed
Conditions
Renal Impairment
Interventions
First Posted Date
2022-05-05
Last Posted Date
2023-04-24
Lead Sponsor
Shionogi
Target Recruit Count
32
Registration Number
NCT05363215
Locations
🇺🇸

Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

🇺🇸

Orlando Clinical Research Center, Inc., Orlando, Florida, United States

🇺🇸

Advanced Pharma CR, LLC, Miami, Florida, United States

and more 1 locations

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

Phase 3
Completed
Conditions
SARS-CoV-2 Infection
Interventions
Drug: Placebo
First Posted Date
2022-03-31
Last Posted Date
2025-05-16
Lead Sponsor
Shionogi
Target Recruit Count
2093
Registration Number
NCT05305547
Locations
🇺🇸

Miami Clinical Research, Miami, Florida, United States

🇺🇸

Vista Health Research, LLC, Miami, Florida, United States

🇮🇳

Tagore Hospital & Research Institute, Jaipur, Rajasthan, India

and more 184 locations

A Study to Assess S-309309 in Healthy and Obese Participants

Phase 1
Completed
Conditions
Obesity
Interventions
First Posted Date
2022-02-21
Last Posted Date
2023-01-11
Lead Sponsor
Shionogi
Target Recruit Count
74
Registration Number
NCT05247970
Locations
🇺🇸

ICON Early Phase Services, LLC, San Antonio, Texas, United States

A Study of S-268019 for the Prevention of COVID-19

Phase 3
Completed
Conditions
SARS-CoV-2
Interventions
Drug: Placebo
First Posted Date
2022-01-28
Last Posted Date
2023-07-25
Lead Sponsor
Shionogi
Target Recruit Count
9902
Registration Number
NCT05212948
Locations
🇻🇳

Buon Ma Thuot City Medical Center, Buon Ma Thuot City, Dak Lak, Vietnam

© Copyright 2025. All Rights Reserved by MedPath